Revertant fibres and dystrophin traces in Duchenne muscular dystrophy: Implication for clinical trials

被引:64
作者
Arechavala-Gomeza, Virginia [1 ]
Kinali, Maria [1 ,2 ]
Feng, Lucy [1 ]
Guglieri, Michela [3 ]
Edge, Geraldine [4 ]
Main, Marion [5 ]
Hunt, David [6 ]
Lehovsky, Jan [7 ]
Straub, Volker [3 ]
Bushby, Kate [3 ]
Sewry, Caroline A. [1 ,8 ]
Morgan, Jennifer E. [1 ]
Muntoni, Francesco [1 ]
机构
[1] UCL, Inst Child Hlth, Dubowitz Neuromuscular Ctr, London WC1N 1EH, England
[2] Hammersmith Hosp, Dept Pediat, London, England
[3] Newcastle Univ, Inst Human Genet, Newcastle Upon Tyne, Tyne & Wear, England
[4] Royal Natl Orthopaed Hosp, Dept Anaesthet, London W1N 6AD, England
[5] Great Ormond St Hosp Sick Children, Dept Physiotherapy, London, England
[6] St Marys Hosp, Dept Orthopaed, London, England
[7] Royal Natl Orthopaed Hosp, Dept Orthopaed, London W1N 6AD, England
[8] RJAH Orthopaed Hosp, Ctr Inherited Neuromuscular Dis, Oswestry, Shrops, England
基金
英国惠康基金;
关键词
Duchenne muscular dystrophy; Revertant fibres; Dystrophin expression; SOMATIC REVERSION SUPPRESSION; POSITIVE FIBERS; MDX MICE; FRAMESHIFT DELETIONS; NONSENSE MUTATION; MUSCLE-FIBERS; EXPRESSION; GENE; RESTORATION; CELLS;
D O I
10.1016/j.nmd.2010.03.007
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Duchenne muscular dystrophy (DMD) is characterised by the absence of dystrophin in muscle biopsies, although residual dystrophin can be present, either as dystrophin-positive (revertant) fibres or traces. As restoration of dystrophin expression is the end point of clinical trials, such residual dystrophin is a key factor in recruitment of patients and may also confound the analysis of dystrophin restoration in treated patients, if, as previously observed in the mdx mouse, revertant fibres increase with age. In 62% of the diagnostic biopsies reports of 65 DMD patients studied, traces or revertants were recorded with no correlation between traces or revertants, the patients' performance, or corticosteroids response. In nine of these patients, there was no increase in traces or revertants in biopsies taken a mean of 8.23 years (5.8-10.4 years) after the original diagnostic biopsy. This information should help in the design and execution of clinical trials focused on dystrophin restoration strategies. (C) 2010 Elsevier B.V. All rights reserved.
引用
收藏
页码:295 / 301
页数:7
相关论文
共 47 条
[31]   DYSTROPHIN EXPRESSION IN DUCHENNE PATIENTS WITH IN-FRAME GENE DELETIONS [J].
NICHOLSON, LVB ;
BUSHBY, KMD ;
JOHNSON, MA ;
GARDNERMEDWIN, D ;
GINJAAR, IB .
NEUROPEDIATRICS, 1993, 24 (02) :93-97
[32]   EXPRESSION OF FULL-LENGTH AND TRUNCATED DYSTROPHIN MINI-GENES IN TRANSGENIC MDX MICE [J].
PHELPS, SF ;
HAUSER, MA ;
COLE, NM ;
RAFAEL, JA ;
HINKLE, RT ;
FAULKNER, JA ;
CHAMBERLAIN, JS .
HUMAN MOLECULAR GENETICS, 1995, 4 (08) :1251-1258
[33]   PREVENTION OF DYSTROPHIC PATHOLOGY IN MDX MICE BY A TRUNCATED DYSTROPHIN ISOFORM [J].
RAFAEL, JA ;
SUNADA, Y ;
COLE, NM ;
CAMPBELL, KP ;
FAULKNER, JA ;
CHAMBERLAIN, JS .
HUMAN MOLECULAR GENETICS, 1994, 3 (10) :1725-1733
[34]   Forced expression of dystrophin deletion constructs reveals structure-function correlations [J].
Rafael, JA ;
Cox, GA ;
Corrado, K ;
Jung, D ;
Campbell, KP ;
Chamberlain, JS .
JOURNAL OF CELL BIOLOGY, 1996, 134 (01) :93-102
[35]   Phase I study of dystrophin Duchenne/Becker plasmid-based gene therapy in muscular dystrophy [J].
Romero, NB ;
Braun, S ;
Benveniste, O ;
Leturcq, F ;
Hogrel, JY ;
Morris, GE ;
Barois, A ;
Eymard, B ;
Payan, C ;
Ortega, V ;
Boch, AL ;
Lejean, L ;
Thioudellet, C ;
Mourot, B ;
Escot, C ;
Choquel, A ;
Recan, D ;
Kaplan, JC ;
Dickson, G ;
Klatzmann, D ;
Molinier-Frenckel, V ;
Guillet, JG ;
Squiban, P ;
Herson, S ;
Fardeau, M .
HUMAN GENE THERAPY, 2004, 15 (11) :1065-1076
[36]  
Schatzberg SJ, 1998, MUSCLE NERVE, V21, P991, DOI 10.1002/(SICI)1097-4598(199808)21:8<991::AID-MUS2>3.3.CO
[37]  
2-S
[38]   QUANTITATION OF MUSCLE FUNCTION IN CHILDREN - A PROSPECTIVE-STUDY IN DUCHENNE MUSCULAR-DYSTROPHY [J].
SCOTT, OM ;
HYDE, SA ;
GODDARD, C ;
DUBOWITZ, V .
MUSCLE & NERVE, 1982, 5 (04) :291-301
[39]  
SHERRAT TG, 1993, AM J HUM GENET, V53, P1007
[40]   EVOLUTIONARY CONSERVATION OF THE DYSTROPHIN CENTRAL ROD DOMAIN [J].
SHERRATT, TG ;
VULLIAMY, T ;
STRONG, PN .
BIOCHEMICAL JOURNAL, 1992, 287 :755-759